OTLC
Price:
$0.05
Market Cap:
$20.41M
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Industry
Biotechnology
IPO Date
1993-08-26
Stock Exchange
OTC
Ticker
OTLC
According to Oncotelic Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -44.15%. This represents a change of 281.12% compared to the average of -11.58% of the last 4 quarters.
The mean historical ROE of Oncotelic Therapeutics, Inc. over the last ten years is -5159.41%. The current -44.15% ROE has changed -99.14% with respect to the historical average. Over the past ten years (40 quarters), OTLC's ROE was at its highest in in the December 2017 quarter at 510.27%. The ROE was at its lowest in in the September 2018 quarter at -1163.79%.
Average
-5159.41%
Median
-59.51%
Minimum
-54824.70%
Maximum
2.90%
Discovering the peaks and valleys of Oncotelic Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 84.05%
Maximum Annual ROE = 2.90%
Minimum Annual Increase = -2750.87%
Minimum Annual ROE = -54824.70%
Year | ROE | Change |
---|---|---|
2024 | -54824.70% | 84.05% |
2023 | -65.15% | -170.96% |
2022 | 91.81% | -164.11% |
2021 | -143.22% | 46.59% |
2020 | -97.70% | 123.52% |
2019 | -43.71% | -105.78% |
2018 | 756.08% | -73.89% |
2017 | 2.90% | -2750.87% |
2016 | -109.23% | 102.80% |
2015 | -53.86% | 23.52% |
The current ROE of Oncotelic Therapeutics, Inc. (OTLC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-18266.01%
5-year avg
-11007.79%
10-year avg
-5159.41%
Oncotelic Therapeutics, Inc.’s ROE is less than ChitogenX Inc. (23.16%), less than Mymetics Corporation (7.69%), greater than ProtoKinetix, Incorporated (-71.40%), less than Statera Biopharma, Inc. (6.68%), less than Sirona Biochem Corp. (65.53%), greater than Kane Biotech Inc. (-727.00%), greater than NervGen Pharma Corp. (-399.62%),
Company | ROE | Market cap |
---|---|---|
23.16% | $305.71K | |
7.69% | $46.00 | |
-71.40% | $3.30M | |
6.68% | $7.14K | |
65.53% | $11.11M | |
-727.00% | $4.79M | |
-399.62% | $200.28M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncotelic Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oncotelic Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Oncotelic Therapeutics, Inc.'s ROE?
How is the ROE calculated for Oncotelic Therapeutics, Inc. (OTLC)?
What is the highest ROE for Oncotelic Therapeutics, Inc. (OTLC)?
What is the 3-year average ROE for Oncotelic Therapeutics, Inc. (OTLC)?
What is the 5-year average ROE for Oncotelic Therapeutics, Inc. (OTLC)?
How does the current ROE for Oncotelic Therapeutics, Inc. (OTLC) compare to its historical average?